Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Chandra Belani"'
Autor:
John Michael Varlotto, Richard Voland, Kerrie McKie, John C. Flickinger, Malcolm M. DeCamp, Debra Maddox, Paul Rava, Thomas J. Fitzgerald, Geoffrey Graeber, Negar Rassaei, Paulo Oliveira, Suhail Ali, Chandra Belani, Jonathan Glanzman, Heather A. Wakelee, Manali Patel, Jennifer Baima, Jianying Zhang, William Walsh
Publikováno v:
Cancer Medicine, Vol 7, Iss 4, Pp 1211-1220 (2018)
Abstract To investigate the interrelation between economic, marital, and known histopathologic/therapeutic prognostic factors in presentation and survival of patients with lung cancer in nine different ethnic groups. A retrospective review of the SEE
Externí odkaz:
https://doaj.org/article/4d9a155402c04c28a6f14d57f308edc6
Autor:
John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, Jenica Upshaw, Thomas J. Fitzgerald, Max Diehn, Christine Lovly, Chandra Belani, Kurt Oettel, Gregory Masters, Matthew Harkenrider, Helen Ross, Suresh Ramalingam, Nathan A. Pennell
Publikováno v:
Clinical Lung Cancer. 23:547-560
ECOG-ACRIN EA5181 is a current prospective, randomized trial that is investigating whether the addition of concomitant durvalumab to standard chemo/radiation followed by 1 year of consolidative durvalumab results in an overall survival benefit over s
Autor:
Amogh Subbakrishna Adishesha, Lily Jakielaszek, Fariha Azhar, Peixuan Zhang, Vasant Honavar, Fenglong Ma, Chandra Belani, Prasenjit Mitra, Sharon Xiaolei Huang
The increasing reliance on online communities for healthcare information by patients and caregivers has led to the increase in the spread of misinformation, or subjective, anecdotal and inaccurate or non-specific recommendations, which, if acted on,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4493f5cdf53e99484159a1d5a4e718b
Autor:
Chandra, Belani, Thomas, Lynch
Publikováno v:
Seminars in oncology. 28
Docetaxel (Taxotere; Aventis, Antony, France) is among the most effective agents for the treatment of non-small cell lung cancer and its use in combination with cisplatin is a logical development. Docetaxel has been combined with cisplatin and is wel
Autor:
Chandra Belani, Suzanne Dahlberg, Julia Bonastre, Bram Ramaekers, Janneke Grutters, Michael Baumann, Manuela Joore, Audrey Mauguen, Béranger Lueza, Aleksander Zajusz, Jean-Pierre PIGNON
Publikováno v:
Journal of Thoracic Oncology, 8(10), 1295-1307. Elsevier Science
Introduction: Modified fractionation radiotherapy (RT), delivering multiple fractions per day or shortening the overall treatment time, improves overall survival for non -small-cell lung cancer (NSCLC) patients compared with conventional fractionatio
Autor:
Rebecca Weinberg, Darryl G.L. Kaurin, Hak Choy, Walter J. Curran, Robert MacRae, Jae Sung Kim, Jaechul Kim, Susan L. Tucker, Philip D. Bonomi, Chandra Belani, George Starkschall
Publikováno v:
Journal of Applied Clinical Medical Physics. 5:15-28
Autor:
Chandra Belani
Publikováno v:
Seminars in Oncology. 29:4-9
In a large, multinational, randomized phase III trial, 1,220 patients with advanced and/or metastatic non-small cell lung cancer were randomized to receive one of three treatments: docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) every 3 weeks; docetax
Autor:
Chandra Belani, Thomas Lynch
Publikováno v:
Seminars in Oncology. 28:10-14
Autor:
Joel S. Greenberger, James R. Jett, Frank Sciurba, Rodney Landreneau, Chandra Belani, A.M. Kalend
Publikováno v:
Radiation Oncology Investigations. 3:243-255
A measurable improvement in the efficacy of the three-dimensional radiotherapy (RT) of primary lung cancer patients with unresectable disease will require the development of a technique that increases the therapeutic ratio of dose delivered to the tu